US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

GRACE THERAPEUTICS INC

2.17

-0.0300-1.36%

Volume:70.87K

Turnover:153.80K

Market Cap:45.65M

PE:-1.81

High:2.23

Open:2.23

Low:2.13

Close:2.20

52wk High:5.18

52wk Low:1.79

Shares:21.04M

Float Shares:15.51M

Volume Ratio:0.98

T/O Rate:0.46%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.2003

EPS(LYR):-0.7916

ROE:-36.19%

ROA:-10.81%

PB:0.95

PE(LYR):-2.74

Loading ...

Overview Company News Filings

Opaleye Management Reports $24,200 Purchase of Grace Therapeutics Shares

Grace Therapeutics (GRCE) Receives a Rating Update from a Top Analyst

Grace Therapeutics Q1 Net Loss Widens on Impairment Charges

Grace Therapeutics Posts Investor Deck on IV Nimodipine Candidate GTx-104 for Aneurysmal Subarachnoid Hemorrhage

Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update

THOMSON REUTERS

Grace Therapeutics, Inc Q1 Net Income USD -15.79 Million

THOMSON REUTERS

Grace Therapeutics, Inc Q1 EPS USD -0.91

THOMSON REUTERS

Grace Therapeutics FY27 Q1 Net Loss Widens to $15.79 Million; Operating Loss Widens to $15.92 Million

Grace Therapeutics to issue 4.762M shares at $2.10 in private placement

Grace Therapeutics Announces $10 Million Private Placement

THOMSON REUTERS

Grace Therapeutics Prices USD 10 Million Private Placement at USD 2.1 Per Share

Grace Therapeutics Announces Annual Shareholder Meeting

Grace Therapeutics Posts Corporate Presentation on GTx-104 IV Nimodipine Program for Aneurysmal Subarachnoid Hemorrhage

Grace Therapeutics receives Type A meeting minutes from FDA

Grace Therapeutics Announces Receipt of Type a Meeting Minutes from U.S. Food and Drug Administration

THOMSON REUTERS

Grace Therapeutics, - Therapeutics Receives FDA Type a Meeting Minutes Regarding April 23, 2026 Crl

THOMSON REUTERS

Craig-Hallum Remains a Buy on Grace Therapeutics (GRCE)

Grace Therapeutics posts corporate presentation highlighting IV nimodipine candidate GTx-104 for aneurysmal subarachnoid hemorrhage

Press Release: Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update

Grace Therapeutics FY26 net loss narrows 18.55% to $7.79 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/GRCE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GRCE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRCE\",,,,,undefined,":{"symbol":"GRCE","market":"US","secType":"STK","nameCN":"GRACE THERAPEUTICS INC","latestPrice":2.17,"timestamp":1787595175100,"preClose":2.2,"halted":0,"volume":70871,"delay":0,"changeRate":-0.013636363636363748,"floatShares":15513699,"shares":21035900,"eps":-1.200273,"marketStatus":"Trading","change":-0.03,"latestTime":"08-24 14:14:48 EDT","open":2.23,"high":2.23,"low":2.13,"amount":153799.6234108,"amplitude":0.045455,"askPrice":2.19,"askSize":862,"bidPrice":2.17,"bidSize":967,"shortable":3,"etf":0,"ttmEps":-1.200273,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"listingDate":1357534800000,"exchange":"NASDAQ","adjPreClose":2.2,"postHourTrading":{"tag":"盘后","latestPrice":2.2,"preClose":2.2,"latestTime":"19:30 EDT","volume":19,"amount":42.3895,"timestamp":1787355005147,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.982219,"impliedVol":0.9333,"impliedVolPercentile":0.4527},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GRCE\",,,,,undefined,":{"symbol":"GRCE","floatShares":15513699,"roa":"-10.81%","roe":"-36.19%","lyrEps":-0.791576,"volumeRatio":0.982219,"shares":21035900,"dividePrice":0,"high":2.23,"amplitude":0.045455,"preClose":2.2,"low":2.13,"week52Low":1.79,"pbRate":"0.95","week52High":5.18,"institutionHeld":0,"latestPrice":2.17,"committee":0.057408,"eps":-1.200273,"divideRate":0,"volume":70871,"delay":0,"ttmEps":-1.200273,"open":2.23,"prevYearClose":3.46,"prevWeekClose":2.2,"prevMonthClose":2.08,"prevQuarterClose":2.27,"fiveDayClose":2.16,"twentyDayClose":2.3,"sixtyDayClose":2.43},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GRCE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"GRCE","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"pre","actualEps":-0.91},{"market":"US","date":"2026-06-18","symbol":"GRCE","fiscalQuarterEnding":"2026/03","expectedEps":-0.24,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1781755200000,"reportTimeType":"pre","actualEps":-0.07},{"market":"US","date":"2026-02-12","symbol":"GRCE","fiscalQuarterEnding":"2025/12","expectedEps":-0.09,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1770872400000,"reportTimeType":"pre","actualEps":-0.26},{"market":"US","date":"2025-11-13","symbol":"GRCE","fiscalQuarterEnding":"2025/09","expectedEps":-0.12,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"pre","actualEps":-0.15},{"market":"US","date":"2025-08-12","symbol":"GRCE","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"","actualEps":-0.21}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GRCE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GRCE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1746244800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GRCE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GRCE","date":"2026-08-21","current":-1.832916,"percent":0.935556,"low":-13.276761,"twenty":-6.470156,"median":-4.317654,"eighty":-2.883162,"high":-1.653321,"avg":-4.935507,"sd":2.494201,"marketCap":45016890},"quantilePoints":[{"date":"2024-10-31","current":-2.746009,"twenty":-2.84522,"median":-2.808016,"eighty":-2.770812,"marketCap":31433569},{"date":"2024-11-08","current":-2.737151,"twenty":-2.770812,"median":-2.746009,"eighty":-2.701719,"marketCap":31332170},{"date":"2024-11-15","current":-2.891861,"twenty":-2.815988,"median":-2.74158,"eighty":-2.694633,"marketCap":33562939},{"date":"2024-11-22","current":-2.821967,"twenty":-2.824979,"median":-2.746009,"eighty":-2.701719,"marketCap":32751751},{"date":"2024-11-29","current":-2.935545,"twenty":-2.870023,"median":-2.76081,"eighty":-2.701719,"marketCap":34069932},{"date":"2024-12-06","current":-3.791745,"twenty":-2.935545,"median":-2.823849,"eighty":-2.717126,"marketCap":44006996},{"date":"2024-12-13","current":-3.407329,"twenty":-3.407329,"median":-2.865651,"eighty":-2.737151,"marketCap":39545457},{"date":"2024-12-20","current":-3.547117,"twenty":-3.407329,"median":-2.887493,"eighty":-2.746009,"marketCap":41167835},{"date":"2024-12-27","current":-3.232594,"twenty":-3.39335,"median":-2.931176,"eighty":-2.746009,"marketCap":37517485},{"date":"2025-01-03","current":-3.494696,"twenty":-3.396845,"median":-2.953018,"eighty":-2.749647,"marketCap":40559444},{"date":"2025-01-10","current":-3.582064,"twenty":-3.494696,"median":-3.066596,"eighty":-2.755568,"marketCap":41573430},{"date":"2025-01-17","current":-2.935545,"twenty":-3.494696,"median":-3.057859,"eighty":-2.767291,"marketCap":34069932},{"date":"2025-01-24","current":-3.437907,"twenty":-3.492949,"median":-3.145227,"eighty":-2.786004,"marketCap":39900353},{"date":"2025-01-31","current":-2.778283,"twenty":-3.476349,"median":-3.13649,"eighty":-2.78702,"marketCap":32244757},{"date":"2025-02-07","current":-2.918071,"twenty":-3.433539,"median":-3.040386,"eighty":-2.785272,"marketCap":33867135},{"date":"2025-02-14","current":-3.040386,"twenty":-3.416065,"median":-3.038201,"eighty":-2.814977,"marketCap":35286716},{"date":"2025-02-21","current":-2.570989,"twenty":-3.416065,"median":-3.009807,"eighty":-2.777013,"marketCap":34374128},{"date":"2025-02-28","current":-2.29038,"twenty":-3.407329,"median":-2.996702,"eighty":-2.746009,"marketCap":30622380},{"date":"2025-03-07","current":-2.050724,"twenty":-3.407329,"median":-2.952538,"eighty":-2.701719,"marketCap":27418184},{"date":"2025-03-14","current":-1.736745,"twenty":-3.389855,"median":-2.935545,"eighty":-2.613138,"marketCap":23220281},{"date":"2025-03-21","current":-1.941514,"twenty":-3.363645,"median":-2.904966,"eighty":-2.495149,"marketCap":25958044},{"date":"2025-03-28","current":-2.329102,"twenty":-3.337435,"median":-2.883124,"eighty":-2.329102,"marketCap":31140100},{"date":"2025-04-04","current":-2.25728,"twenty":-3.328698,"median":-2.865651,"eighty":-2.3283,"marketCap":30179833},{"date":"2025-04-11","current":-1.99051,"twenty":-3.319961,"median":-2.825732,"eighty":-2.29038,"marketCap":26613125},{"date":"2025-04-17","current":-2.093114,"twenty":-3.278025,"median":-2.81323,"eighty":-2.187348,"marketCap":27984936},{"date":"2025-04-25","current":-2.441966,"twenty":-3.253562,"median":-2.777648,"eighty":-2.187348,"marketCap":32649092},{"date":"2025-05-02","current":-2.780558,"twenty":-3.243078,"median":-2.76081,"eighty":-2.203926,"marketCap":37176067},{"date":"2025-05-09","current":-2.872902,"twenty":-3.234341,"median":-2.778283,"eighty":-2.214186,"marketCap":38410696},{"date":"2025-05-16","current":-2.784047,"twenty":-3.204636,"median":-2.778283,"eighty":-2.249072,"marketCap":37222708},{"date":"2025-05-23","current":-3.04702,"twenty":-3.183669,"median":-2.787433,"eighty":-2.28376,"marketCap":40738659},{"date":"2025-05-30","current":-2.978583,"twenty":-3.159206,"median":-2.802024,"eighty":-2.29493,"marketCap":39823661},{"date":"2025-06-06","current":-3.037068,"twenty":-3.145227,"median":-2.825732,"eighty":-2.310491,"marketCap":40605593},{"date":"2025-06-13","current":-2.996026,"twenty":-3.145227,"median":-2.855425,"eighty":-2.319966,"marketCap":40056869},{"date":"2025-06-20","current":-3.149932,"twenty":-3.145227,"median":-2.867837,"eighty":-2.32375,"marketCap":42114585},{"date":"2025-06-27","current":-4.249161,"twenty":-3.190658,"median":-2.872902,"eighty":-2.328621,"marketCap":40655972},{"date":"2025-07-03","current":-4.523767,"twenty":-3.242086,"median":-2.883124,"eighty":-2.331154,"marketCap":43283399},{"date":"2025-07-11","current":-4.480408,"twenty":-3.326951,"median":-2.892641,"eighty":-2.341415,"marketCap":42868542},{"date":"2025-07-18","current":-4.841731,"twenty":-3.403834,"median":-2.918071,"eighty":-2.351675,"marketCap":46325682},{"date":"2025-07-25","current":-4.624937,"twenty":-3.433539,"median":-2.930636,"eighty":-2.361936,"marketCap":44251398},{"date":"2025-08-01","current":-4.176896,"twenty":-3.536633,"median":-2.935545,"eighty":-2.372196,"marketCap":39964544},{"date":"2025-08-08","current":-4.263614,"twenty":-3.615264,"median":-2.954985,"eighty":-2.392716,"marketCap":40794257},{"date":"2025-08-15","current":-4.12993,"twenty":-3.770777,"median":-2.969531,"eighty":-2.448122,"marketCap":42591970},{"date":"2025-08-22","current":-4.424925,"twenty":-4.171115,"median":-2.986997,"eighty":-2.477228,"marketCap":45634254},{"date":"2025-08-29","current":-4.00925,"twenty":-4.24627,"median":-2.996702,"eighty":-2.502733,"marketCap":41347400},{"date":"2025-09-05","current":-4.103112,"twenty":-4.234708,"median":-3.005439,"eighty":-2.533069,"marketCap":42315399},{"date":"2025-09-12","current":-4.317654,"twenty":-4.278067,"median":-3.026807,"eighty":-2.55483,"marketCap":44527969},{"date":"2025-09-19","current":-4.183566,"twenty":-4.278067,"median":-3.037068,"eighty":-2.570221,"marketCap":43145113},{"date":"2025-09-26","current":-4.12993,"twenty":-4.263614,"median":-3.042574,"eighty":-2.570989,"marketCap":42591970},{"date":"2025-10-03","current":-4.049477,"twenty":-4.249161,"median":-3.047328,"eighty":-2.593742,"marketCap":41762257},{"date":"2025-10-10","current":-4.049477,"twenty":-4.234708,"median":-3.057723,"eighty":-2.595872,"marketCap":41762257},{"date":"2025-10-17","current":-4.304246,"twenty":-4.234708,"median":-3.067849,"eighty":-2.613138,"marketCap":44389684},{"date":"2025-10-24","current":-4.223792,"twenty":-4.234708,"median":-3.088369,"eighty":-2.616494,"marketCap":43559970},{"date":"2025-10-31","current":-4.277428,"twenty":-4.249161,"median":-3.127753,"eighty":-2.626653,"marketCap":44113112},{"date":"2025-11-07","current":-4.472902,"twenty":-4.277428,"median":-3.147579,"eighty":-2.626653,"marketCap":46129039},{"date":"2025-11-14","current":-4.561183,"twenty":-4.285293,"median":-3.197647,"eighty":-2.667694,"marketCap":47039480},{"date":"2025-11-21","current":-5.673105,"twenty":-4.29252,"median":-3.241803,"eighty":-2.677955,"marketCap":44363684},{"date":"2025-11-28","current":-5.745374,"twenty":-4.304791,"median":-3.258804,"eighty":-2.688958,"marketCap":44928827},{"date":"2025-12-05","current":-5.926046,"twenty":-4.321299,"median":-3.328698,"eighty":-2.692631,"marketCap":46341683},{"date":"2025-12-12","current":-6.070584,"twenty":-4.338036,"median":-3.37675,"eighty":-2.699947,"marketCap":47471968},{"date":"2025-12-19","current":-6.628899,"twenty":-4.37129,"median":-3.407329,"eighty":-2.701719,"marketCap":51837987},{"date":"2025-12-26","current":-6.668474,"twenty":-4.381422,"median":-3.416065,"eighty":-2.710963,"marketCap":52147467},{"date":"2026-01-02","current":-6.846564,"twenty":-4.398844,"median":-3.485959,"eighty":-2.725136,"marketCap":53540129},{"date":"2026-01-09","current":-7.519348,"twenty":-4.414931,"median":-3.520906,"eighty":-2.740694,"marketCap":58801298},{"date":"2026-01-16","current":-7.202743,"twenty":-4.455514,"median":-3.582064,"eighty":-2.746009,"marketCap":56325454},{"date":"2026-01-23","current":-7.519348,"twenty":-4.480408,"median":-3.617011,"eighty":-2.747222,"marketCap":58801298},{"date":"2026-01-30","current":-6.945503,"twenty":-4.55824,"median":-3.673799,"eighty":-2.75382,"marketCap":54313831},{"date":"2026-02-06","current":-6.886139,"twenty":-4.648062,"median":-3.931533,"eighty":-2.762708,"marketCap":53849610},{"date":"2026-02-13","current":-6.985078,"twenty":-4.841731,"median":-3.987126,"eighty":-2.771641,"marketCap":54623311},{"date":"2026-02-20","current":-10.093444,"twenty":-4.899543,"median":-4.005898,"eighty":-2.777013,"marketCap":60348701},{"date":"2026-02-27","current":-10.662818,"twenty":-5.673105,"median":-4.00925,"eighty":-2.778283,"marketCap":63752987},{"date":"2026-03-06","current":-9.731115,"twenty":-5.727307,"median":-4.042772,"eighty":-2.778283,"marketCap":58182337},{"date":"2026-03-13","current":-10.507534,"twenty":-5.781509,"median":-4.049477,"eighty":-2.780558,"marketCap":62824545},{"date":"2026-03-20","current":-11.335714,"twenty":-6.052517,"median":-4.059534,"eighty":-2.784047,"marketCap":67776233},{"date":"2026-03-27","current":-12.345058,"twenty":-6.411233,"median":-4.103112,"eighty":-2.790819,"marketCap":73811104},{"date":"2026-04-02","current":-12.629745,"twenty":-6.628899,"median":-4.116521,"eighty":-2.790819,"marketCap":75513246},{"date":"2026-04-10","current":-9.368786,"twenty":-6.676389,"median":-4.12993,"eighty":-2.808748,"marketCap":56015974},{"date":"2026-04-17","current":-11.620401,"twenty":-6.830734,"median":-4.143339,"eighty":-2.82022,"marketCap":69478376},{"date":"2026-04-24","current":-6.081947,"twenty":-6.945503,"median":-4.152369,"eighty":-2.824979,"marketCap":36363961},{"date":"2026-05-01","current":-5.79726,"twenty":-6.898012,"median":-4.170157,"eighty":-2.82971,"marketCap":34661818},{"date":"2026-05-08","current":-5.823141,"twenty":-6.854479,"median":-4.172168,"eighty":-2.8423,"marketCap":34816558},{"date":"2026-05-15","current":-5.667857,"twenty":-6.830734,"median":-4.183566,"eighty":-2.861561,"marketCap":33888116},{"date":"2026-05-22","current":-5.79726,"twenty":-6.747625,"median":-4.205691,"eighty":-2.865651,"marketCap":34661818},{"date":"2026-05-29","current":-6.288992,"twenty":-6.727837,"median":-4.223792,"eighty":-2.868274,"marketCap":37601883},{"date":"2026-06-05","current":-6.185469,"twenty":-6.727837,"median":-4.223792,"eighty":-2.87175,"marketCap":36982922},{"date":"2026-06-12","current":-5.952544,"twenty":-6.715965,"median":-4.241935,"eighty":-2.872902,"marketCap":35590259},{"date":"2026-06-18","current":-5.745499,"twenty":-6.69222,"median":-4.270521,"eighty":-2.876991,"marketCap":34352337},{"date":"2026-06-26","current":-4.949242,"twenty":-6.668474,"median":-4.278067,"eighty":-2.883124,"marketCap":38569441},{"date":"2026-07-02","current":-4.677764,"twenty":-6.668474,"median":-4.285293,"eighty":-2.883132,"marketCap":36453818},{"date":"2026-07-10","current":-5.095422,"twenty":-6.665043,"median":-4.29252,"eighty":-2.884902,"marketCap":39708623},{"date":"2026-07-17","current":-5.032773,"twenty":-6.646837,"median":-4.29252,"eighty":-2.892173,"marketCap":39220402},{"date":"2026-07-24","current":-4.907476,"twenty":-6.628899,"median":-4.30561,"eighty":-2.897526,"marketCap":38243961},{"date":"2026-07-31","current":-4.322755,"twenty":-6.628899,"median":-4.314302,"eighty":-2.913943,"marketCap":33687233},{"date":"2026-08-07","current":-4.42717,"twenty":-6.609111,"median":-4.322755,"eighty":-2.918071,"marketCap":34500935},{"date":"2026-08-14","current":-2.153423,"twenty":-6.549748,"median":-4.335879,"eighty":-2.918071,"marketCap":43544375},{"date":"2026-08-21","current":-2.226244,"twenty":-6.470156,"median":-4.317654,"eighty":-2.883162,"marketCap":45016890}],"updateTime":1787572998104},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GRCE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660440417","title":"Opaleye Management Reports $24,200 Purchase of Grace Therapeutics Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2660440417","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660440417?lang=en_us&edition=fundamental","pubTime":"2026-08-19 19:45","pubTimestamp":1787139924,"startTime":"0","endTime":"0","summary":"Opaleye Management reports $24,200 purchase of Grace Therapeutics sharesOpaleye Management, led by President James Silverman, bought 11,608 Grace Therapeutics common shares at a weighted average USD 2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDLFL6Jq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Opaleye Management Reports $24,200 Purchase of Grace Therapeutics Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GRCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660460128","title":"Grace Therapeutics (GRCE) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2660460128","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660460128?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:15","pubTimestamp":1787058955,"startTime":"0","endTime":"0","summary":"In a report released today, Chase Knickerbocker from Craig-Hallum reiterated a Buy rating on Grace Therapeutics, with a price target of $4.00. Acco...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/grace-therapeutics-grce-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/grace-therapeutics-grce-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GRCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659154351","title":"Grace Therapeutics Q1 Net Loss Widens on Impairment Charges","url":"https://stock-news.laohu8.com/highlight/detail?id=2659154351","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659154351?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:08","pubTimestamp":1786622937,"startTime":"0","endTime":"0","summary":"Grace Therapeutics Q1 net loss widens on impairment chargesOverviewUS biopharma firm's Q1 net loss widened on impairment charges tied to deprioritized programsResearch and admin expenses fell as GTx-1","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE","PLRX","BK4007","AARD","ELOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659879154","title":"Grace Therapeutics Posts Investor Deck on IV Nimodipine Candidate GTx-104 for Aneurysmal Subarachnoid Hemorrhage","url":"https://stock-news.laohu8.com/highlight/detail?id=2659879154","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659879154?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:06","pubTimestamp":1786622803,"startTime":"0","endTime":"0","summary":"Grace Therapeutics posts investor deck on IV nimodipine candidate GTx-104 for aneurysmal subarachnoid hemorrhageGrace Therapeutics outlined a path to resubmit the GTx-104 IV nimodipine NDA following an FDA Type A meeting.Complete response letter centered on CMC and manufacturing; no clinical safety or efficacy deficiencies cited, no additional clinical data requested.Strategy targets dual-source manufacturing, with remediation at the current CDMO requiring FDA reinspection, alongside US second-source transfer.Phase 3 STRIVE-ON safety trial met its primary endpoint, with clinically significant hypotension in 28% on GTx-104 vs 35% oral capsules.Data showed 54% of GTx-104 patients received at least 95% of prescribed dose vs 8% for oral capsules; 90-day good recovery rose 29%.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational pu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL7DtnyM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659259151","title":"Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659259151","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659259151?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:00","pubTimestamp":1786622405,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUAC0RHJ4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRCE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659151420","title":"Grace Therapeutics, Inc Q1 Net Income USD -15.79 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659151420","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659151420?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:00","pubTimestamp":1786622404,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXD0T0L7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRCE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659151408","title":"Grace Therapeutics, Inc Q1 EPS USD -0.91","url":"https://stock-news.laohu8.com/highlight/detail?id=2659151408","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659151408?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:00","pubTimestamp":1786622404,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXD0T0L7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRCE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659715924","title":"Grace Therapeutics FY27 Q1 Net Loss Widens to $15.79 Million; Operating Loss Widens to $15.92 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659715924","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659715924?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:34","pubTimestamp":1786620842,"startTime":"0","endTime":"0","summary":"Grace Therapeutics FY27 Q1 net loss widens to $15.79 million; operating loss widens to $15.92 millionGrace Therapeutics posted a net loss of USD 15.79 million, widening from USD 3.36 million in the ye","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL48Hzrf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657517484","title":"Grace Therapeutics to issue 4.762M shares at $2.10 in private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2657517484","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657517484?lang=en_us&edition=fundamental","pubTime":"2026-08-05 17:35","pubTimestamp":1785922526,"startTime":"0","endTime":"0","summary":"Grace Therapeutics (GRCE) announced that it has entered into a securities purchase agreement for a private placement financing with new and existin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/grace-therapeutics-to-issue-4-762m-shares-at-2-10-in-private-placement-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/grace-therapeutics-to-issue-4-762m-shares-at-2-10-in-private-placement-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","GRCE","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657862596","title":"Grace Therapeutics Announces $10 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2657862596","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657862596?lang=en_us&edition=fundamental","pubTime":"2026-08-05 09:01","pubTimestamp":1785891669,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nTUA5JNG8H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GRCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657596895","title":"Grace Therapeutics Prices USD 10 Million Private Placement at USD 2.1 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2657596895","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657596895?lang=en_us&edition=fundamental","pubTime":"2026-08-05 09:01","pubTimestamp":1785891664,"startTime":"0","endTime":"0","summary":"Grace Therapeutics prices USD 10 million private placement at USD 2.1 per shareGrace Therapeutics priced a $10 million private placement of 4,761,904 common shares at USD 2.1 each.Deal expected to clo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL69cjJB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","BK4585","SG9999014039.USD","SG9999014005.SGD","LU2095319765.USD","BK4588","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","NDAQ","LU2210150020.SGD","LU2210149790.SGD","LU0314104364.USD","IE00BN0W2W23.USD","BCDF","IE00B64PRP62.GBP","GRCE","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4007","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655838369","title":"Grace Therapeutics Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2655838369","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655838369?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:31","pubTimestamp":1785270667,"startTime":"0","endTime":"0","summary":"Grace Therapeutics announces annual shareholder meetingGrace Therapeutics will hold its annual shareholder meeting virtually on Sept. 17, 2026.Shareholders will vote on electing five directors to one-","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL62y86f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654096940","title":"Grace Therapeutics Posts Corporate Presentation on GTx-104 IV Nimodipine Program for Aneurysmal Subarachnoid Hemorrhage","url":"https://stock-news.laohu8.com/highlight/detail?id=2654096940","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654096940?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:23","pubTimestamp":1785237828,"startTime":"0","endTime":"0","summary":"Grace Therapeutics posts corporate presentation on GTx-104 IV nimodipine program for aneurysmal subarachnoid hemorrhageGrace Therapeutics outlined a targeted FDA NDA resubmission plan for IV nimodipin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL9t1X73:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GRCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654009687","title":"Grace Therapeutics receives Type A meeting minutes from FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2654009687","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654009687?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:16","pubTimestamp":1785237408,"startTime":"0","endTime":"0","summary":"Grace Therapeutics (GRCE) announced receipt of the FDA meeting minutes from a Type A meeting held with the FDA to discuss the complete response let...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/grace-therapeutics-receives-type-a-meeting-minutes-from-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/grace-therapeutics-receives-type-a-meeting-minutes-from-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","BK4139","BK4007","LENZ","GRCE","LABU","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654006557","title":"Grace Therapeutics Announces Receipt of Type a Meeting Minutes from U.S. Food and Drug Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2654006557","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654006557?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:00","pubTimestamp":1785236400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nTUABXTQGJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GRCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654006293","title":"Grace Therapeutics, - Therapeutics Receives FDA Type a Meeting Minutes Regarding April 23, 2026 Crl","url":"https://stock-news.laohu8.com/highlight/detail?id=2654006293","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654006293?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:00","pubTimestamp":1785236400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nTUABXTQGJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GRCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651178969","title":"Craig-Hallum Remains a Buy on Grace Therapeutics (GRCE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651178969","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651178969?lang=en_us&edition=fundamental","pubTime":"2026-07-14 15:25","pubTimestamp":1784013940,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Grace Therapeutics. The company’s shares closed ye...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-remains-a-buy-on-grace-therapeutics-grce-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-remains-a-buy-on-grace-therapeutics-grce-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","GRCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644859450","title":"Grace Therapeutics posts corporate presentation highlighting IV nimodipine candidate GTx-104 for aneurysmal subarachnoid hemorrhage","url":"https://stock-news.laohu8.com/highlight/detail?id=2644859450","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644859450?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:43","pubTimestamp":1781786631,"startTime":"0","endTime":"0","summary":"Grace Therapeutics posts corporate presentation highlighting IV nimodipine candidate GTx-104 for aneurysmal subarachnoid hemorrhage. Grace Therapeutics highlighted GTx-104, an intravenous nimodipine candidate for aneurysmal subarachnoid hemorrhage, positioning it as a potential alternative to oral nimodipine.Phase 3 STRIVE-ON safety trial met its primary endpoint, showing 28% clinically significant hypotension with GTx-104 versus 35% with oral capsules.Trial data showed 54% of GTx-104 patients received at least 95% of prescribed dose intensity versus 8% for oral capsules.90-day outcomes showed a 29% relative increase in good recovery versus oral capsules; trial was not powered for statistical comparisons.FDA issued a Complete Response Letter in April 2026 citing CMC and manufacturing readiness; no clinical deficiencies identified; company plans an NDA resubmission.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strive","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL4wvMbX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644208337","title":"Press Release: Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2644208337","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644208337?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:00","pubTimestamp":1781784000,"startTime":"0","endTime":"0","summary":"Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission. Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences. Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA. \"Since receipt of the U.S. Food and Drug Administration's  Complete Response Letter  in April 2026, we have been working diligently on addressing the cited items, and we look forward to a constructive discussion with the FDA as we continue to prepare our resubmission,\" said Prashant Kohli, CEO of Grace Therapeutics. \"FDA approval of our New Drug Application  for GTx-104 for the treatment of aSAH would represent the first meaningful innovation in the standard of care for these patients in more than 40 years. As evidenced by the response among researchers, practitioners and industry leaders to the presentation of our Phase 3 STRIVE-ON trial results at major medical conferences throughout the fiscal year, we believe the","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443465.HKD","LU0971096721.USD","IE00BFMHRM44.USD","LU2237443895.HKD","BK4530","IE00BFXG1179.USD","ICU","LU2237443382.USD","IE00BKVL7J92.USD","LU1363072403.SGD","LU0170899867.USD","LU2746668974.SGD","LU0128526141.USD","LU0882574139.USD","BK4121","BK4585","LU0390134368.USD","RDI","LABU","GRCE","BK4588","LU2746668461.USD","LENZ","IE00BZ1G4Q59.USD","IE00BHPRN162.USD","LU0029874061.USD","BK4539","BK4007","LU0267386448.USD","LU1815336091.USD","BK4108","LU0149725797.USD","BK4139","CRL","IE00B1BXHZ80.USD","LU2237443978.SGD","CMC","LU2237443622.USD","BK4082","BK4006","LU2237443549.SGD","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644408850","title":"Grace Therapeutics FY26 net loss narrows 18.55% to $7.79 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2644408850","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644408850?lang=en_us&edition=fundamental","pubTime":"2026-06-18 19:32","pubTimestamp":1781782379,"startTime":"0","endTime":"0","summary":"Grace Therapeutics posted a fiscal 2026 net loss of USD 7.79 million, narrowing from the prior year; loss per share improved to USD 0.47.Research and development expense fell to USD 2.41 million from USD 9.51 million, while general and administrative expense rose to USD 8.67 million.Cash and cash equivalents ended March 31, 2026 at USD 16.98 million, down from USD 22.13 million a year earlier.The board decided not to resume internal funding for GTx-102 or GTx-101; it expects USD 9.2 million and USD 4.3 million impairment charges in fiscal 2027 Q1.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grace Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL85QL6Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GRCE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":36,"code":"91000000","status":"200"}]}}